🤖 Search 5,000+ AI tools Ask our bot for help →

Discover the latest tools and trends in AI 🔮

Join 60,000+ subscribers including Amazon, Apple, Google, and Microsoft employees reading our free newsletter.

[email protected] Subscribe

Nabla Bio lands $26M Series A funding round

Nabla Bio lands $26M Series A funding round
Nabla Bio lands $26M Series A funding round

Nabla Bio, a Cambridge, MA-based AI and biotech company, has secured $26M in Series A funding.

The round was led by Radical Ventures, with participation from existing investors and strategic partners AstraZeneca, Bristol Myers Squibb, and Takeda.

The funds will be used to scale operations and enhance development efforts, particularly in AI-driven drug design and high-throughput drug function measurement technologies.

Co-founded by Surge Biswas and Frances Anastassacos, Nabla Bio specializes in creating atomically precise drug designs, focusing initially on antibodies for targets such as GPCRs, ion channels, and transporters.

Comments